Equities researchers at Piper Jaffray Companies assumed coverage on shares of Teleflex Incorporated (NYSE:TFX) in a report released on Friday. The brokerage set an “overweight” rating and a $295.00 price target on the medical technology company’s stock. Piper Jaffray Companies’ target price points to a potential upside of 16.65% from the stock’s current price.

Several other equities research analysts have also issued reports on TFX. BidaskClub lowered Teleflex from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Jefferies Group LLC reissued a “buy” rating and set a $230.00 price target on shares of Teleflex in a research report on Thursday, August 3rd. Needham & Company LLC reissued a “buy” rating on shares of Teleflex in a research report on Friday, August 4th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $238.00 target price (up from $220.00) on shares of Teleflex in a research report on Wednesday, August 9th. Finally, Zacks Investment Research lowered Teleflex from a “buy” rating to a “hold” rating in a research report on Thursday, August 24th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $274.44.

Shares of Teleflex (NYSE TFX) opened at $252.89 on Friday. The company has a debt-to-equity ratio of 0.88, a quick ratio of 3.70 and a current ratio of 4.72. The stock has a market capitalization of $11,392.44, a P/E ratio of 31.26, a P/E/G ratio of 2.17 and a beta of 1.05. Teleflex has a 52-week low of $141.41 and a 52-week high of $263.97.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.01 by $0.11. The business had revenue of $534.70 million for the quarter, compared to analyst estimates of $522.94 million. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. The business’s revenue was up 17.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.80 EPS. research analysts predict that Teleflex will post 8.32 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Piper Jaffray Companies Initiates Coverage on Teleflex Incorporated (TFX)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/11/12/piper-jaffray-companies-initiates-coverage-on-teleflex-incorporated-tfx.html.

In other news, Director Stephen K. M.D. Klasko sold 200 shares of the firm’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $211.75, for a total transaction of $42,350.00. Following the transaction, the director now directly owns 8,080 shares of the company’s stock, valued at $1,710,940. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 600 shares of company stock worth $138,162 over the last ninety days. 2.39% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. Neuberger Berman Group LLC increased its holdings in shares of Teleflex by 0.5% during the second quarter. Neuberger Berman Group LLC now owns 5,708 shares of the medical technology company’s stock valued at $1,186,000 after purchasing an additional 28 shares during the period. Stifel Financial Corp increased its holdings in shares of Teleflex by 0.6% during the second quarter. Stifel Financial Corp now owns 5,399 shares of the medical technology company’s stock valued at $1,121,000 after purchasing an additional 31 shares during the period. Toronto Dominion Bank increased its holdings in shares of Teleflex by 14.5% during the second quarter. Toronto Dominion Bank now owns 552 shares of the medical technology company’s stock valued at $115,000 after purchasing an additional 70 shares during the period. Xact Kapitalforvaltning AB increased its holdings in shares of Teleflex by 2.7% during the second quarter. Xact Kapitalforvaltning AB now owns 3,482 shares of the medical technology company’s stock valued at $723,000 after purchasing an additional 90 shares during the period. Finally, World Asset Management Inc increased its holdings in shares of Teleflex by 3.6% during the second quarter. World Asset Management Inc now owns 2,942 shares of the medical technology company’s stock valued at $611,000 after purchasing an additional 101 shares during the period. 89.79% of the stock is currently owned by institutional investors.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Analyst Recommendations for Teleflex (NYSE:TFX)

Receive News & Stock Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related stocks with our FREE daily email newsletter.